Fig. 6
From: Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
Mass spectra of Aβ1-40 and its proteolytic products in PBS (a), after incubation with 5% serum with b no antibody, c in the presence of Solanezumab, d Crenezumab, and e Bapineuzumab